Paricalcitol
mRNA synthesis
In vitro transcription of capped mRNA with modified nucleotides and Poly(A) tail
Tyramide Signal Amplification (TSA)
TSA (Tyramide Signal Amplification), used for signal amplification of ISH, IHC and IC etc.
Phos Binding Reagent Acrylamide
Separation of phosphorylated and non-phosphorylated proteins without phospho-specific antibody
Cell Counting Kit-8 (CCK-8)
A convenient and sensitive way for cell proliferation assay and cytotoxicity assay
SYBR Safe DNA Gel Stain
Safe and sensitive stain for visualization of DNA or RNA in agarose or acrylamide gels.
Inhibitor Cocktails
Protect the integrity of proteins from multiple proteases and phosphatases for different applications.
Paricalcitol是第三代维生素D类似物,也是VDR的选择性激活剂,用于治疗继发性甲状旁腺功能亢进。Paricalcitol也直接影响慢性肾病中的血管钙化过程[1]。
维生素D在各种生理过程中起着重要作用,主要参与钙磷稳态和骨代谢。对于自身免疫性疾病动物模型和患者,维生素D可以预防或改善炎性疾病。维生素D调节炎症反应的机制依赖于调节性CD4+T细胞的活化[2]。
腹腔注射Paricalcitol可以调节腹膜透析液(PDF)诱导的腹膜纤维化。Paricalcitol治疗降低了腹膜中的IL-17水平。体外研究表明,CD4+和CD8+调节性T细胞影响IL-17调节。给予Paricalcitol显著促进CD8+和CD4+调节性T细胞形成。然而,Paricalcitol增加体内的CD4+和CD8+调节性T细胞数目。总之,VDR信号通路激活的免疫调节机制可以防止或减少纤维化,如PDF在小鼠中诱导的腹膜纤维化。在Gentamicin诱导的大鼠肾损伤模型中,Paricalcitol抑制炎性细胞因子、核因子κB表达、磷酸化ERK1/2表达以及粘附分子(单核细胞趋化蛋白-1、ICAM-1和VCAM-1)的增加,并逆转转化生长因子(TGF)-β1诱导的上皮间质转化过程和细胞外基质积聚[2]。
根据非透析慢性肾病患者的肾病情况,对其继发性甲状旁腺功能亢进进行治疗。结果表明,Paricalcitol对蛋白尿具有良好的疗效。Paricalcitol显著减少(配对t检验)24小时尿蛋白UA(P < 0.011)和24小时尿蛋白定量UQP(P < 0.0001)。尿白蛋白肌酐比(UACR)的减少不显著(P = 0.074)。在观察期内,24小时动态血压无统计学意义。在伴有继发性甲状旁腺功能亢进和蛋白尿的非透析慢性肾病患者中,给予1 mg的Paricalcitol(临床用量)可以显著降低24小时尿蛋白和24小时尿蛋白定量,而对24小时动态血压没有显著影响[3]。
参考文献:
[1]Darko Duplancic, Marijan Cesarik, Nikola Kolja Poljak et al. The influence of selective vitamin D receptor activator paricalcitol on cardiovascular system and cardiorenal protection. Clinical Interventions in Aging 2013:8 149–156
[2]Guadalupe T. Gonzalez-Mateo et al. Paricalcitol Reduces Peritoneal Fibrosis in Mice through the Activation of Regulatory T Cells and Reduction in IL-17 Production. PLOS ONE October 2014 | Volume 9 | Issue 10 | e108477
[3]Nina Hojs, Sebastjan Bevc et al. Paricalcitol Reduces Proteinuria in Non-Dialysis Chronic Kidney Disease Patients Therapeutic Apheresis and Dialysis 2013; 17(4):368–372
Physical Appearance | A crystalline solid |
Storage | Store at -20°C |
M.Wt | 416.64 |
Cas No. | 131918-61-1 |
Formula | C27H44O3 |
Synonyms | Zemplar |
Solubility | Soluble in water |
Chemical Name | (1R,3R)-5-[(2E)-2-[(1R,3aS,7aR)-1-[(E,2R,5S)-6-hydroxy-5,6-dimethylhept-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]cyclohexane-1,3-diol |
SDF | Download SDF |
Canonical SMILES | CC(C=CC(C)C(C)(C)O)C1CCC2C1(CCCC2=CC=C3CC(CC(C3)O)O)C |
运输条件 | 蓝冰运输或根据您的需求运输。 |
一般建议 | 不同厂家不同批次产品溶解度各有差异,仅做参考。若实验所需浓度过大至产品溶解极限,请添加助溶剂助溶或自行调整浓度。溶液形式一般不宜长期储存,请尽快用完。 |